Abrahão Cunha Thays Crosara, Gontijo Couto Ana Claudia, Januzzi Eduardo, Rosa Ferraz Gonçalves Rafael Tardin, Silva Graziella, Silva Cassia Regina
Post-Graduated Program Genetics and Biochemistry, Institute of Biotechnology, Federal University of Uberlândia, Uberlândia, MG, Brazil.
Post-Graduated Program Orofacial Pain, CIODONTO, Belo Horizonte, MG, Brazil.
Toxicon X. 2021 Sep 2;12:100083. doi: 10.1016/j.toxcx.2021.100083. eCollection 2021 Nov.
The use of botulinum neurotoxin-A (BoNT-A) is an alternative for the management of orofacial pain disorders. Although only Botox has labeled, there are other commercial brands available for use, among them: Dysport, Botulift, Prosigne, and Xeomin. The objective of the present study was to evaluate the possible differences in the antinociceptive effect evoked by different commercially available formulations of BoNT-A in an animal model of inflammatory orofacial pain induced by formalin injection. Male C57/BL6 mice (20-25 g) were submitted to the pre-treatment with five different commercial brands of BoNT-A (Botox, Botulift, Xeomin, Dysport, or Prosigne; with doses between 0.02 and 0.2 Units of Botulinum Toxin, in 20 μL of 0.9% saline) three days prior the 2% formalin injection. All injections were made subcutaneously into the right perinasal area. After formalin injections, nociceptive behaviors like rubbing the place of injection were quantified during the neurogenic (0-5 min) and inflammatory (15-30 min) phases. The treatment using Botox, Botulift, and Xeomin were able to induce antinociceptive effects in both phases of the formalin-induced pain animal model, however, Dysport and Prosigne reduced the response in neither of them. Our data suggest that the treatment using different formulations of BoNT-A is not similar in efficacy as analgesics when evaluated in formalin-induced orofacial pain in mice.
使用A型肉毒杆菌神经毒素（BoNT-A）是治疗口面部疼痛障碍的一种替代方法。虽然只有保妥适有相关标签，但也有其他可供使用的商业品牌，其中包括：吉适、Botulift、Prosigne和司库奇尤单抗。本研究的目的是评估在福尔马林注射诱导的炎性口面部疼痛动物模型中，不同市售剂型的BoNT-A所诱发的抗伤害感受作用可能存在的差异。雄性C57/BL6小鼠（20-25克）在注射2%福尔马林前三天，用五种不同商业品牌的BoNT-A（保妥适、Botulift、司库奇尤单抗、吉适或Prosigne；剂量为0.02至0.2单位肉毒杆菌毒素，溶于20微升0.9%盐水中）进行预处理。所有注射均皮下注射到右侧鼻周区域。福尔马林注射后，在神经源性（0-5分钟）和炎性（15-30分钟）阶段，对诸如摩擦注射部位等伤害感受行为进行量化。使用保妥适、Botulift和司库奇尤单抗的治疗能够在福尔马林诱导的疼痛动物模型的两个阶段诱导抗伤害感受作用，然而，吉适和Prosigne在这两个阶段均未降低反应。我们的数据表明，在小鼠福尔马林诱导的口面部疼痛模型中进行评估时，使用不同剂型的BoNT-A治疗作为镇痛药的疗效并不相似。
